Work

Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.8034

Authors: Shaji Kumar, William Bensinger, Craig B. Reeder, Todd M. Zimmerman, James R. Berenson, Guohui Liu, Deborah Berg, Neeraj Gupta, Alessandra Di Bacco, Ai-Min Hui, Ruben Niesvizky

Institutions: Mayo Clinic, Fred Hutch Cancer Center, Mayo Clinic in Arizona, University of Chicago, Institute for Myeloma & Bone Cancer Research, Takeda Oncology (United States), NewYork–Presbyterian Hospital, Cornell University

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2800089216

Cites:

Cited by: 13

Related to: 10